Equity Details
Price & Market Data
Price: $3.20
Daily Change: +$0.142 / 4.42%
Daily Range: $3.06 - $3.36
Market Cap: $116,657,352
Daily Volume: 1,484,089
Performance Metrics
1 Week: -1.94%
1 Month: 4.83%
3 Months: 75.10%
6 Months: 59.34%
1 Year: 20.26%
YTD: 15.88%
About NRx Pharmaceuticals, Inc. (NRXP)
Essential market data for NRx Pharmaceuticals, Inc. (NRXP). The stock is trading at 3.20, with a daily change of +$0.142 / 4.42%. Market cap: 116,657,352. Review its performance across all major time intervals.
Details
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
